New cancer drug AB598 enters first human tests

NCT ID NCT05891171

Ongoing Disease control Sponsor: Arcus Biosciences, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 5 times

Summary

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AB598 (an experimental drug) given alone or with zimberelimab, fluorouracil, leucovorin, and oxaliplatin
What this could lead to: If successful, this could point toward a new treatment option for several advanced cancers.
What could go wrong: This is a very early, small Phase 1 trial focused on safety, not effectiveness. The drug may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer cervical cancer esophageal cancer Esophageal Neoplasms gastric adenocarcinoma gastric cancer gastric neoplasm gastroesophageal cancer gastroesophageal junction adenocarcinoma head and neck squamous cell carcinoma metastatic malignant neoplasm neoplasm non-small cell lung carcinoma ovarian cancer renal cell carcinoma Squamous Cell Carcinoma of Head and Neck triple-negative breast carcinoma urinary bladder carcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCER ADVANCED MALIGNANCIES BLADDER CANCER CERVICAL CANCER ESOPHAGEAL CANCER GASTRIC CANCER GASTROESOPHAGEAL-JUNCTION CANCER (GEJ) HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC) NON-SMALL CELL LUNG CANCER (NSCLC) OVARIAN CANCER RENAL CELL CARCINOMA (RCC) TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Locations

Research Site

Phoenix, Arizona, 85054, United States
Research Site

Jacksonville, Florida, 32224, United States
Research Site

Lake City, Florida, 32024, United States
Research Site

Hinsdale, Illinois, 60521, United States
Research Site

Detroit, Michigan, 48201, United States
Research Site

Rochester, Minnesota, 55905, United States
Research Site

New Brunswick, New Jersey, 08901, United States
Research Site

Canton, Ohio, 44718, United States
Research Site

Cleveland, Ohio, 44106, United States
Research Site

Irving, Texas, 75039, United States
Research Site

Fairfax, Virginia, 22031, United States
Research Site

Adelaide, Australia
Research Site

Tainan, Taiwan
Research Site

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.